Ron Najafi, PhD, CEO of Emery Pharma: Advancing Early Disease Detection with Cutting-Edge Innovation
Dr. Ron Najafi (CEO of Emery Pharma) describes recent advances in pharmaceutical and analytical chemistry that enable earlier disease detection and more personalized treatments. He highlights improved ability to analyze large panels of inflammatory proteins (e.g., from synovial fluid) and argues earlier-stage detection (stage one) opens wider prevention and treatment opportunities. The tone is optimistic about increased diagnostics, treatments, and prevention compared with 10–20 years ago.
Chapters
More from Dr.
Hippocrates said, let thy food be thy medicine #obesity #metabolicsyndrome #lustig #shorts #health
Bill Wilson, MD: Why GLP-1 Drugs Are Overpriced—and How Compounding and Competition Could Fix It
Nitrosamine in Pharmaceutical Products? A Deep Dive into Risk Management by Ron Najafi, Ph.D.
The Subcellular Processes That Belie All Chronic Disease. The Hateful (or Grateful) Eight #lustig
Bill Wilson, MD: GLPs May Reverse Carb Syndrome—Helping Patients Reach Zero and Sustain with Diet
Why Everything You Knew About Obesity Is Wrong | Dr. Robert Lustig on Sugar & Metabolic Syndrome
Robert Lustig, MD: How Fructose Fuels Fatty Liver, Oxidative Stress, and Metabolic Disease #fructose
Robert Lustig, MD: The 3 Types of Fat Fueling Insulin Resistance and Disease #insulin resistance
Bill Wilson, MD: GLPs May Reverse CARB Syndrome. Helping Patients Reach Zero and Sustain with Diet